9-13 May 2012 • Barcelona, Spain - Estro-events.org

9-13 May 2012 • Barcelona, Spain
ESTRO
I FInal announcement I
9-13 May 2012 • Barcelona, Spain
31

Table of
con conTen enTs
CME ACCREDITATION
The conference organizers have applied for CMe accreditation with the
accreditation Council of Oncology in europe (aCOe) & european accreditation
Council for Continuing Medical education (eaCCMe).
DEADLINES
abstract submission deadline: 16 January 2012
early registration: 12 January 2012
Late registration: 10 April 2012
Desk registration: as of 11 April 2012
ESTRO
31
2012
> InTRODuCTIOn 4
> SCIenTIFIC COMMITTeeS 5
> PRe-MeeTIng COuRSeS 6
> WHaT’S neW aT eSTRO 31? 11
> COnTOuRIng WORKSHOPS 12
> SCIenTIFIC PROgRaMMe 13
> aWaRDS 22
> CaLL FOR abSTRaCTS 23
> geneRaL InFORMaTIOn 26
> RegISTRaTIOn 28
> aCCOMMODaTIOn 30
> MeMbeRSHIP 32
Page 2 /// FInal announcement /// eSTRO 31 eSTRO 31 /// FInal announcement /// Page 3

Vincenzo Valentini
Introduct
ntroductIon on
a LeTTeR OF WeLCOMe FROM THe COnFeRenCe CHaIRPeRSOnS
It is our pleasure to invite you to attend eSTRO 31 in barcelona from 9 to 13 May 2012.
eSTRO is an interdisciplinary society where radiation oncologists, medical physicists, biologists,
radiation technologists and nurses work for the benefit of cancer patients, looking at the collaboration
with all the organisations in force in the oncology field. In eSTRO 31 the multidisciplinarity
and interdisciplinary components of our practice will be reviewed, emphasising on
the new opportunities that they represent for all of us. national Societies and allied Oncology
Organisations will convene to join efforts in promoting standards and outcome survey.
at eSTRO 31 meeting the most up-to-date evidence in clinical, physics, radiobiology and oncology
science and technology will be presented, and a broad portfolio of educational opportunities will be
provided. Life in the eSTRO house will also be enlightened by special interdisciplinary sessions in a
dedicated room which will jointly address relevant topics for radiation oncologists, physicists, radiobiologists
and RTTs in the same forum, allowing each discipline to enrich their knowledge base.
Symposia and debates are foreseen on new evidence - for the more common tumours and for the
Núria Jornet
challenging unusual clinical presentations - as well as in biology, imaging, physics and technology.
This includes the integration of molecular and genetic prediction of tumour and normal tissue response, the
combination of radiation therapy with new and more efficient molecular targeted drugs, a more extensive use
of particle therapies to better spare normal tissues, a complete integration of 4D image guided treatments,
the development of adaptive radiation therapy to the most active part of the tumours as defined by functional
imaging and the curative use of stereotactic radiotherapy. all these advances challenge machine and patient
specific Qa and dosimetry as well as the training and practice of radiation technologists.
eSTRO 31 will start with a series of pre-meeting workshops and courses which will be followed by an
opening ceremony in the evening.
after the great success of the contouring workshops at eSTRO 29 in barcelona and London, we will continue
with this initiative. Keep an eye on upcoming eSTRO communications to learn more about the tumour sites
that will be covered.
as in previous conferences, eSTRO 31 will continue to offer an additional Young Scientists Track. This track is
fully organised by our young members and it enables them to share common interests.
The number of submitted abstracts to eSTRO meetings increases year after year. Therefore, eSTRO 31 will include
a large poster exhibition and a poster reception on the Thursday evening. The challenge we now face is to
increase the visibility and display of these posters and to facilitate networking between professionals working on
the same or similar topics. Poster viewing will be improved by a better distribution in time and space of posters;
by a special electronic poster viewing system that will be available during the whole conference; and also, by
special poster discussion sessions which will ensure maximum visibility for the most promising posters.
all of the leading exhibitors will contribute to eSTRO 31, europe’s largest industrial exhibition in radiation oncology,
offering the opportunity to view the latest products and services in cancer treatment and cancer care.
Sincerely,
Vincenzo Valentini & Núria Jornet
Chairpersons of the Scientific Programme Committee
Scientific
committee
ommitteeS
eSTRO 31
SCIenTIFIC PROgRaMMe COMMITTee
chaIrs: V. Valentini (IT), n. Jornet (eS)
members: M. baumann (De), J. bourhis (FR ), C. Clark (gb),
D. georg (aT ), C. Haie-Meder (FR ), D. Hollywood (Ie),
T. Knöös (Se ), P. Lambin (nL), M. Mast (nL), L. Muren (DK),
J. Overgaard (DK), D. Pasini (IT), R. Pötter (De), S. Rivera
(FR), H. P. Rodemann (De), F. Stewart (nL), D. Verellen (be),
b. Wouters (Ca)
SCIenTIFIC aDVISORY COMMITTee
OF YOung eSTRO MeMbeRS
chaIrs: C. Clark (gb), S. Rivera (FR)
members: P. blanchard (FR), b. eberle (CH), a. Filippi (IT),
e. gershkevitsh (ee), J. Jaal (ee), M. niyazi (De), D. Jurado
(eS), M. Krause (De), L. Livi (IT), P. Munck af Rosenschöld
(DK), F. Moura (PT), P. Petrič (SL), K. Tanderup (DK)
SCIenTIFIC aDVISORY COMMITTee
CLInICaL RaDIOTHeRaPY
chaIr: D. Hollywood (Ie)
members: C. belka (De), S. bodis (CH), R. Dziadziuszko
(PO), J. giralt (eS), C. grau (DK), K. Harrington (gb),
K. Haustermans (be), b. Jereczek-Fossa (IT), a. Kiltie
(gb), V. Khoo (gb), e. Lartigau (FR), P. Maingon (FR),
a.H. Ree (nO), M. Verheij (nL), D. Zips (De)
SCIenTIFIC aDVISORY COMMITTee
bRaCHYTHeRaPY
chaIr: C. Haie-Meder (FR)
members: a. bossi (FR), P. Hoskin (gb), g. Kovács (De),
J.C. Lindegaard (DK), a. Polo (eS), C. Polgár (Hu), F.a.
Siebert (De), J. Skowronek (PO), e. Van Limbergen (be),
J. Venselaar (nL)
ESTRO
31
2012
SCIenTIFIC aDVISORY COMMITTee
RaDIaTIOn PHYSICS
chaIr: T. Knöös (Se)
members: M. do Carmo Lopes (PT), C. Fiorino (IT), R. garcia
(FR), D. georg (aT), b. Heijmen (nL), C. Hurkmans (nL),
b. Mc Clean (Ie), R. Moeckli (CH), H. nyström (Se), D.R.
Olsen (nO), C. brink (DK), C. garibaldi (IT), C. Kirisits
(aT), J. Malicki (PO), H. Palmans (gb), D. Thwaites (auS),
a. Torresin (IT), u. Van der Heide (nL), T. Wiezorek (De)
SCIenTIFIC aDVISORY COMMITTee
RaDIObIOLOgY
chaIr: b. Wouters (Ca)
members: J. alsner (DK), a. begg (nL), W. Dörr (De), J. Kaanders
(nL), R. Tarnawski (PO), T. brunner (gb), n. Cordes (De),
T. Helleday (gb), P.C. Lara (eS), M. Martin (FR), M. Pruschy
(CH), H. P. Rodemann (De), M.C. Vozenin (FR)
SCIenTIFIC aDVISORY COMMITTee
RaDIaTIOn TeCHnOLOgY
chaIrs: D. Pasini (IT), M. Mast (nL)
members: a. boejen (DK), M. Coffey (Ie), V. Karadza (HR),
M. Kamphuis (nL), g. McColl (nL), a. Osztavics (aT),
b. Speleers (be), a. Vaandering (be)
LOCaL ORganISIng COMMITTee
chaIrs: a. Ramos aguerri (eS), C. Munoz Montplet (eS)
Page 4 /// FInal announcement /// eSTRO 31 eSTRO 31 /// FInal announcement /// Page 5

Pre re-M -Meeting eeting CCourses
ourses
CLInICaL PRe-MeeTIng COuRSe • WeDneSDaY, 9 MaY 2012
InnOVaTIOn In IMagIng ReLeVanT FOR THe RaDIaTIOn OnCOLOgISTS anD THe RaDIOLOgISTS
Jointly organised with ESOR
course dIrectors:
P. Lambin (nL) and L. Marti-bonmarti (eS)
course aIms:
This course, jointly organized by eSTRO and eSOR (european School of Radiology), aims at promoting an integrated approach
between specialists involved in multidisciplinary tumour boards to tailor the best treatment for each individual
patient by exploiting the use of imaging.
new advanced imaging technology not only provides morphological information on tumour extension, but also information
on tumour function and biology. It not only allows a good evaluation of tumour response during and after treatment,
but also an early detection of tumour recurrence. Radiation oncologists increasingly use hybrid equipment in which
diagnostic imaging technology is incorporated within the radiation treatment machines to allow continuous adaptation
of radiation treatment according to the daily response of the tumour, the surrounding organs and their movement.
Thus there is a growing interest to enhance the collaboration between imaging specialists to optimise and to adapt the
different uses of imaging to the comprehensive clinical management of the oncological patient.
by the combination of lectures and case discussions, this course aims to offer a programme focusing on the use of imaging
in a truly multidisciplinary environment to support understanding between different specialists’ needs, practising
common language and delineating research perspectives.
Who should attend?
The target group consists of radiation oncologists and senior residents and junior radiologists who are interested in
learning and improving their knowledge on an optimal approach to multidisciplinary treatment management exploiting
the use of imaging.
content:
• Innovation in hardware: PeT- MR, dual energy CT,
• Quantification of imaging: standardisation in PeT, diffusion MR, quantification of response, how to get more out of
imaging,
• What do we need to know in a multidisciplinary tumour board? Head and neck cancer, lung cancer, prostate cancer,
rectum cancer.
RaDIObIOLOgY PRe-MeeTIng COuRSe • WeDneSDaY, 9 MaY 2012
ESTRO
31
2012
COMbInIng RaDIaTIOn WITH TaRgeTeD THeRaPIeS: COnCePTS, OPPORTunITIeS anD PITFaLLS
course dIrectors:
C. Vens (nL) and a. Chalmers (gb)
course aIms:
Research into the mechanisms underlying resistance of tumours to radiation therapy has identified a number of key pathways
that could be targeted in order to improve tumour control. and advances in drug development have provided us
with new drugs to manipulate these pathways. but only a few of these targeted agents have been successfully combined
with radiation therapy in the clinic, and the results have been mixed. The aim of this course is to provide an overview of
the key concepts and pathways involved, and to discuss progress made and problems encountered in bringing radiation/
targeted therapy combinations to the clinic.
Who should attend the course?
The course is targeted at radiation oncologists who may be aware of the existence of targeted therapies, and may even
have prescribed them, but would like to learn more. In particular we will try to explain why and how these agents can
be combined with radiation therapy. Research or scientific experience is not required, but the course will also be of
interest to scientists undertaking radiation related research.
content:
The course will provide an overview of targeted therapy concepts in four areas that are relevant to radiation responses
of tumours:
• Dna damage responses (including Dna repair and cell cycle checkpoints),
• Signal transduction pathways (including egFR, PI3K and related pathways),
• Tumour microenvironment (including hypoxia, integrins and cancer stem cells),
• angiogenesis.
There will then be a session on how to determine which patients are likely to benefit from which combinations. This
will include aspects of biomarker development including imaging, pathology, clinical features and molecular subtyping.
The final session will focus on clinical application of these concepts. Here we will consider what we have learned from
those clinical trials that have been conducted – both positive and negative – and how we can select the best drugs and
design the best clinical studies. The course will finish with a vision of the future in which combinations of radiation and
targeted therapies are considered to be ‘standard of care’.
a panel of invited international speakers will provide high quality talks that are specifically tailored to our target audience.
In between talks there will be lots of opportunities (and much encouragement) for spirited discussion involving
faculty and delegates.
Page 6 /// FInal announcement /// eSTRO 31 eSTRO 31 /// FInal announcement /// Page 7

PHYSICS PRe-MeeTIng COuRSe • WeDneSDaY, 9 MaY 2012
course dIrector:
H. nyström (Se)
Pre re-M -Meeting eeting CCourses
ourses
WHaT a PHYSICIST SHOuLD COnSIDeR beFORe gOIng InTO a PROTOn THeRaPY PROJeCT
course aIms:
In many countries in europe as well as in the rest of the world, proton therapy facilities are either in the process of
being created or are already well-established. In fact, the increase in the number of new facilities has been more or
less exponential for many years, leading to an increased demand for medical physicists capable of carrying out proton
therapy projects.
There are many obvious advantages when using proton therapy compared to conventional photon based radiotherapy,
since a significantly larger fraction of the absorbed dose is actually delivered to the target volumes and an overall superior
dose distribution is achieved.
However, substantial differences exist in terms of technology, treatment planning, dosimetry, Qa etc. What is a reasonable
staffing level? What is a reasonable “business plan”? How should acceptance testing be performed? What are
the demands for clinical commissioning? What are the demands for treatment planning? What are the demands for Qa?
This course aims at answering a few of the above-mentioned questions and at giving an overview of the particular aspects
of radiotherapy that are specific to proton therapy. In particular those involved in the start up phase of a proton
therapy project or those that are considering entering into such a project would benefit from participation.
Who should attend?
The participant in the course is expected to be a medical physicist experienced in conventional radiotherapy but curious
about proton therapy.
content:
• Introduction to the physics and basic dosimetry of protons,
• acceptance testing and clinical commissioning of scanned and scattered proton beams,
• Treatment planning for protons, including margin concepts,
• CT scanning and the handling of image artefacts,
• Obtaining an efficient patient flow in a multi gantry PT facility,
• Qa and verification planning.
ESTRO
31
2012
PHYSICS PRe-MeeTIng COuRSe • WeDneSDaY, 9 MaY 2012
JoIntly organIsed by gec-estro brachyphysIcs group and estro physIcs commIttee
ReCenT aDVanCeS In bRaCHYTHeRaPY PHYSICS
course dIrectors:
J. LM Venselaar (nL) and D. baltas (De)
course aIms:
• To demonstrate the most recent developments in brachytherapy physics: a discussion on recent and future societal
reports and recommendations,
• To discuss the developments in source calibration, quality assurance, and new equipment,
• To discuss the steps towards modern 3D conformal image based brachytherapy,
• To discuss new and forthcoming advanced treatment planning: model based dose calculation algorithms and inverse
planning and optimisation methodologies in intensity modulated brachytherapy,
• To discuss the similarities and differences between modern 3D conformal eRT and bRT and its consequences for the
concepts of margins.
Who should attend?
The course is aimed primarily at medical physicists and medical physicists in training, and at radiation technologists
willing to update themselves on the latest developments in brachytherapy physics. a basic knowledge of brachytherapy
physics is required.
content:
• Status of present day brachytherapy physics: weak and strong points, challenges and possibilities, and recent technological
developments,
• Calibration of sources, RaKR/Sk, and/or dose-to-water concept (iMeRa project); dosimetry chain from PSDL to enduser,
• new approaches in brachytherapy dose calculation: model based dose calculation algorithms (MC, grid based boltzmann
solvers, primary/scatter separation),
• Inverse planning and optimisation methodologies in intensity modulated brachytherapy,
• Image guided brachytherapy: use of CT and MRI, uS (and PeT) in bT, choice of settings, sequences, fusion, functional
imaging,
• Specific Qa requirements for modern imaging procedures in RT and bT,
• uncertainties associated with the physical aspects: calibration and dose calculation,
• uncertainties associated with the clinical steps: accuracy in imaging, reconstruction, delivery, implications of inter/
intrafraction movement,
• Similarities and differences in modern 3D conformal eRT and bRT and its consequences for margin concepts,
• In-vivo dosimetry: techniques and possible applications.
Page 8 /// FInal announcement /// eSTRO 31 eSTRO 31 /// FInal announcement /// Page 9

Pre re-M -Meeting eeting CCourses
ourses Scientific
cientific PProgramme
rogramme
RTT PRe-MeeTIng COuRSe • WeDneSDaY, 9 MaY 2012
THe DeLIneaTIOn OF nORMaL STRuCTuReS: PRaCTICe anD CHaLLengeS
course dIrectors:
D. Pasini (IT) and S. Rivera (FR)
course aIms:
Intensity Modulated Radiotherapy Techniques (Static or rotational IMRT-techniques) rather than uniform intensity techniques
give the ability to conform dose distributions to a variety of complex tumour sites/volumes while sparing nearby
critical normal tissue structures (OaR) as possible.
The QuanTeC reports have summarised the evidence from a wide range of studies relating to the dose tolerance of the
main OaRs. Several of the reports highlight the issue of the normal tissue delineation considering both anatomical and
functional aspects.
In order to achieve a greater level of accuracy in the definition of OaRs, there is an urgent need to improve the knowledge
of the anatomical limits of some selected structures. It is therefore important to become familiar with contouring
procedures on the different imaging modalities implemented in the treatment planning systems, without neglecting the
organ dose-volume tolerance.
This course will specifically focus on the anatomical definition of normal structures within the head and neck, thorax
and pelvic regions.
an introductory lecture will illustrate the meaning of OaR delineation within the frame of the QuanTeC report.
The following section will be organised in:
1) a first theoretical part for each site, where an expert will give an overview of the delineation of the selected organ/s
at risk in accordance with the QuanTeC recommendations,
2) It will be followed by a practical session in which the participants will have the opportunity to apply their knowledge
in practice with the support of the faculty. They will be asked to contour organs on FaLCOn, an e-learning software
tool based on the eDuCaSe platform of eSTRO which has already been used successfully during previous workshops
on target volume delineation.
In preparation for the course and to ensure maximum benefit, the participants will be asked to use the FaLCOn platform
at home to delineate selected organs at risk. The same exercise will be repeated during the course and, after the experts’
lectures, the comparison between the exercises will be discussed by the teachers using FaLCOn tools.
as an outcome of the course we would like the participants to review their clinical practice in the context of the new
recommendations of normal structure delineation and QuanTeC guidelines.
Who should attend?
This course is designed for radiation technologists involved in planning and radiation oncologists in training.
content:
• anatomical definition of selected normal structures,
• Review of dose-volume tolerance for the selected organs based on the new evidences,
• Improving the practice on contouring.
WHaT’S neW aT eSTRO 31?
ESTRO
31
2012
1. The scientific programme of eSTRO 31 will be enriched by special sessions in an ‘Interdisciplinary Track’ where relevant
topics for radiation oncologists, physicists, radiobiologists and RTTs will be addressed jointly. not sure which
sessions you could attend? To make it more convenient for you, for each session of this track, the discipline of relevance
is indicated.
2. Have a closer look at the ‘Look Inside’ (LI) sessions. The format of these sessions allows for approximately 66% of the
time for presentation of theory followed by approximately 33% of the time for illustration via practical examples.
3. Debates (D) have been designed in the Oxford example with point and counterpoint discussions followed by conclusions
in support and against of the stance taken by the debaters.
4. We continue in the tradition of Joint Sessions (JS) with other societies such as aSTRO, eau, eCCO, eFOMP, eSMO,
eSSO, eORTC, eanM and PROS.
5. need some guidance in deciding which sessions would be most beneficial for you to attend? Here are the topics
that will be addressed on the main conference days.
thursday, 10 may 2012
The small volume challenge; Cutting edge technology; Data management and networks; Targeting perspective in
Radiobiology; adaptive RT: changing the practice
FrIday, 11 may 2012
The children, young and elderly patients deal; Theragnostic and Imaging in RT; Quality assurance of new techniques
and technologies; Microenvironment
saturday, 12 may 2012
Current practice and moving controversies; Dosimetry challenges; Theragnostic and Imaging in RT; normal tissue;
Radiobiological principles for RTT practice
sunday, 13 may 2012
Current practice and moving controversies; Predictive biomarkers in RT; Dose calculation and optimization; Looking
forward; Stem cells; RTT responsibilities and involvement in research
Page 10 /// FInal announcement /// eSTRO 31 eSTRO 31 /// FInal announcement /// Page 11

workshops
orkshops
COnTOuRIng WORKSHOPS
Inconsistencies in contouring target and critical structures can seriously undermine the precision of conformal radiation
therapy planning and are generally considered to be the biggest and most unpredictable source of errors in radiation
oncology.
eSTRO started with the organisation of contouring sessions in barcelona at eSTRO 29.
This first experience was very positive and the barcelona sessions were quickly fully booked.
The Scientific Committee of the London meeting and the eSTRO education and Training committee therefore decided to
repeat these very useful workshops in 2011 and in the meantime they have become an indispensable and very attractive
part of the annual meeting.
at eSTRO 31 in barcelona, we will be pleased to offer the 4 contouring workshops to a limited number of participants
(60/workshop) on the following sites:
prostate
breast
gynaecology
CnS
The main aims will be to strengthen hands-on contouring skills and discuss the intercomparison of the different delineated
volumes with experts in the field and colleagues from all over the world. Participants will be allowed to bring their
own laptop or use an eSTRO laptop to participate online.
For more details on the experts chairing these workshops and the practical organisation please check the eSTRO website:
www.estro-events.org/Pages/eSTRO31.aspx
We recommend not to wait too long to register or you might discover
that the workshop you want to attend is already fully booked!
Scientific
Programme
rogramme
PRE-MEETINg COuRSES • WEDNESDAy, 9 MAy 2012
ESTRO
31
2012
CliniCal Radiobiology PhysiCs PhysiCs RTT
Innovation in imaging
relevant to the
Radiation Oncologist
and the Radiologist
Page 12 /// FInal announcement /// eSTRO 31 eSTRO 31 /// FInal announcement /// Page 13
18:00 –
19:15
19:30
Course DIrector:
P. Lambin (NL) and
L. Marti-Bonmarti (ES)
OPenIng CeReMOnY
WeLCOMe ReCePTIOn
Combining radiation What a physicist
with targeted therapies: should consider before
concepts, opportunities going into a proton
and pitfalls
therapy project
course DIrectors:
A. Chalmers (GB)
and C. Vens (NL)
course DIrector:
H. Nyström (SE)
See pages 6-10 for complete information on pre-meeting courses
Recent advances in
brachytherapy physics
course DIrectors:
D. Baltas (DE)
and J. Venselaar (NL)
The delineation of
normal structures:
practice and challenges
course DIrectors:
D. Pasini (IT)
and S. Rivera (IT)

BARCELONA • ThuRSDAy, 10 MAy 2012
Scientific
cientific PProgramme
rogramme
clInIcal clInIcal InterdIscIplInary physIcs physIcs radIobIology RTT
Adaptive
radiotherapy:
changing the
practice
Targeting
Data
management
and networks
Cutting edge
technology
The small volume challenge
topIcs
oF the day
JOInT WITH
InTeRDISCIPLInaRY
TL
The DNA damage response
following irradiation and
its significance
TL
Biostatistics
for medical
physicists
TL
Flattening filter free
photon beams
TL
Adaptive radiotherapy state
of the art
TL
When is hypofractionation
mandatory:
the radiobiologist’s and
clinician’s point of view?
TL
Extra cranial stereotactic:
from technical
availabilities to clinical
opportunities
08:00 – 08:40
JOInT WITH
InTeRDISCIPLInaRY
S
Synthetic lethal approaches
in radiotherapy
- exploiting mutations
• exploiting hypoxia
dependent Dna repair
defects
• The use of functional
screens to identify novel
targets of radiosensitisation
• Synthetic lethal
approaches for RaS using
biologics
S
hot research issues in
ion beam therapy
• Ion species beyond
protons and carbon
ions
• Single particle tomography
for verifying
ion beam delivery
• Treatment planning:
integrating robustness
in optimisation
Sa
Adaptive radiotherapy:
opportunities and pitfalls
CL, Ph, BRT, RB, RTT
• Decision rules for re-planning
• Can deformable registration
approaches be reliable?
• Strategies for dose accumulation
in adaptive radiation
therapy
• biological adaptation strategies
JS
ESTRO - EAu
The challenge of treating
early intermediate risk prostate
cancer
• Is dose escalation appropriate?
• Innovative surgery:
opportunities and constraints
- Robotic
• Innovative surgery: opportunities
and constraints
- Laparoscopic
• The role of androgen blockade
combined with radiotherapy
S
Clinical achievements in
extra cranial stereotactic:
facts or promises
• Stages I-II nSCLC
• Liver
• Spinal / paraspinal
08:45 – 10:00
10:00 – 10:30 COFFee bReaK
PP PP PP PP
10:30 – 11:30 PP PP Sb
Adaptive radiotherapy: how
to handle the tumour modification
along the treatment
CL, Ph, BRT, RB, RTT
• Head and neck
• Lung
• gynaecology
PRESIDENTIAL SyMPOSIuM: The reverse angle perspective
• Rapid Learning Health care & Randomised trial: are the two approaches antagonistic or complementary? - P. Lambin (NL)
• What is the scientific community expecting from eSTRO to build a multidisciplinary platform in europe? - C. van de Velde (NL)
11:45 – 12:30
SESSIONS: TL= Teaching Lecture / S = Symposium /JS = Joint Symposium / D = Debate / PP = Proffered Papers / LI = Look Inside / EU = Session on EU Projects
DISCIPLINES: CL= Clinical / PH= Physics / BRT= Brachytherapy / RB= Radiobiology / RTT= Radiation Technology
Page 14 /// FInal announcement /// eSTRO 31 eSTRO 31 /// FInal announcement /// Page 15
clInIcal clInIcal InterdIscIplInary physIcs physIcs radIobIology RTT
aWaRD LeCTuRe (Van DeR SCHueRen)
12:30 – 13.00
13:00 – 14:30 LunCH anD InDuSTRY SYMPOSIa
S
Adaptive radiotherapy:
changing the practice
• aRT: Problems &
possible solutions for
RTTs
• aRT in Head and
neck: how it affects
the practice
• aRT by gating
• aRT in brachytherapy
S
Radiotherapy and the
immune system, immunological
aspects of
treatment response to
ionizing radiation
• Role of CD8+ and
dendritic cells in the
treatment response
to ionizing radiation
• TgF-β signalling orchestrates
late renal
toxicity by regulating
the immune response
after irradiation
• effects of modulated
immune responses on
epithelial radiation
effects during fractionated
irradiation
JS
ESTRO - EFOMP
Sharing information and
communication in radiation
oncology
• Workflow in radiotherapy.
network architecture and
transmission standards from
the images to treatment and
dosimetric verification
• Improving standards for
interoperability in radiation
oncology:
DICOM and IHe-RO
• networking and connectivity
in radiotherapy: opportunities
and risks
• Internationally advanced computer
network for research
and decision supporting
software
LI
Cutting edge technology;
can we deliver
the dose distribution
we plan?
• external radiation
therapy with photons
• Ion beam therapy
• brachytherapy
S
Brachytherapy boost
or SIB: treatment of
choice for prostate
cancer?
CL, Ph, BRT
• Imaging in target
definition
• Comparison between
brachytherapy and
ebT with x-rays
and protons. Dose
distributions and
peripheral doses
• emerging data for
high risk patients
S
hypofractionation and
volume effect in breast
cancer
• update of hypofractionation
in WbRT and
implications for PbRT
• How important is the
volume effect for late
adverse effects after
aPbI?
• update of IORT trials
• update of brachytherapy
trials
JS
ESTRO - ECCO
Ethics in professional
life
14:30 – 15:45
15:45 – 16:15 COFFee bReaK
PP PP D
This house believes
that daily verification
and image analysis is
solely the responsibility
of the radiation
oncologist
D
This house believes
that process-based
quality management
replaces today’s quality
controls
16:15 - 17:15 PP PP D
Debate: This house
believes that brachytherapy
is the best
technique for partial
breast irradiation
CL, BRT
HIgHLIgHTS OF THe PROFFeReD PaPeRS
17:30 – 18:30
POSTeR ReCePTIOn - POSTeR aWaRDS
18:30 – 19:30
SESSIONS: TL= Teaching Lecture / S = Symposium /JS = Joint Symposium / D = Debate / PP = Proffered Papers / LI = Look Inside / EU = Session on EU Projects
DISCIPLINES: CL= Clinical / PH= Physics / BRT= Brachytherapy / RB= Radiobiology / RTT= Radiation Technology

BARCELONA • FRIDAy, 11 MAy 2012
Scientific
cientific PProgramme
rogramme
clInIcal clInIcal InterdIscIplInary physIcs physIcs radIobIology RTT young
Microenvironment Elderly patients
in radiotherapy
departments
Quality assurance
of new techniques
and technologies
Theragnostic and imaging
in radiotherapy
The children, young
and elderly patients deal
topIcs
oF the day
TL
how to design your
study
TL
Increased number
of elderly cancer
patients: general
overview
TL
Clinical relevance
of tumour microenvironment
and
metabolism
TL
Streamlining IMRT
QA
TL
Physical and geometricaluncertainties
in functional
imaging and how to
deal with them
TL
Decision support
systems: requirements,implementation
and evaluation
TL
Current practice
and moving points:
paediatrics
08:00 – 08:40
JOInT WITH RTTs
S
Oncology safety:
learning from
experience
• Physics perspective
on incidents
• Clinician perspective
on incidents
• Incidents in related
areas: surgery
• Incidents in related
areas: medical
oncology
• Discussion
S
Radiotherapy in
elderly: where are
we aiming for in the
future
• elderly with
cancer: is it necessary
to change
the radiotherapy
protocol?
• Informing and
communicating
with elderly radiotherapy
patients
• guidelines to
treat patients
with orthopaedic
prosthesis
S
Tumour microenvironment
– novel
biology and novel
targets
• Microenvironmental
response to
phosphoinositide-3
kinase inhibition:
effects on cancer
therapy
• novel targets of
hypoxia tolerance
• Targeting vasculogenesis
to improve
radiation response
S
Dose assessment
during treatment;
towards greater
control of the dose
delivered to the
patient
• Dose reconstruction
using dynamic
log files and CbCT
• Dose reconstruction
using ePID
and CbCT
• Dose reconstruction
in tomotherapy
• Implantable MOS-
FeT dosimeters
Sa
Emerging imaging
technologies –applications
in radiation
oncology
CL, Ph, RB
• Radiomics:
advanced image
processing
approach
• new tracers
• Dual energy CT
• MRI and PeT scanner
JS
ESTRO – ESMO – ESSO
young adult
patients: the maximum
derivable or
the minimum effective
treatment
• Combined treatments
in Hodgkin
disease: the radiotherapy
optimal
dose
• breast cancer in
young women:
adjuvant therapy
and fertility considerations
• Combined treatment
rectal: young
adult patients
JS
ESTRO - PROS
Complex multimodel
approaches:
Paediatrics
• new perspectives
with protons /
particles
• new knowledge
on late effects:
second primary
cancers, cardiac
and cerebrovascular
diseases
• Technical advances
in radiotherapy for
medulloblastoma:
yesterday, today,
tomorrow
• update on neuroblastoma
08:45 – 10:00
10:00 – 10:30 COFFee bReaK
10:30 – 11:30 SeLeCTeD RanDOMIZeD TRIaLS PP PP PP
hIghLIghTS OF RANDOMISED TRIALS
11:45 – 12:15
aWaRD LeCTuRe (RegauD)
12:15 – 13:00
13:00 – 14:30 LunCH anD InDuSTRY SYMPOSIa Lunch symposium:
Education and working
around Europe
SESSIONS: TL= Teaching Lecture / S = Symposium /JS = Joint Symposium / D = Debate / PP = Proffered Papers / LI = Look Inside / EU = Session on EU Projects
DISCIPLINES: CL= Clinical / PH= Physics / BRT= Brachytherapy / RB= Radiobiology / RTT= Radiation Technology
Page 16 /// FInal announcement /// eSTRO 31 eSTRO 31 /// FInal announcement /// Page 17
clInIcal InterdIscIplInary physIcs physIcs radIobIology RTT young
S
ESTRO
contract
with the
young
JOInT
WITH
CLInICIanS
LI
Does fractionated
radiation therapy make
tumours more aggressive?
• Radiation induced
changes in cell-cell and
cell-matrix
• Vascular and metabolic
responses to tumour
irradiation
• TgFbeta: dual roles
in the response of
tumours and normal
tissues to radiation
LI
Tracking: techniques, methods,
dosimetric and QA aspects
• Motivation for real-time adaptive
therapy (what problems
are solved, how important is
this potentially, what level of
evidence is there)
• approaches for motion detection
and trajectory prediction
• Clinical commissioning and clinical
experience of real-time
adaptation
S
Imaging for treatment
assessment
• Cone beam CT based
measurement of dose
response in normal lung
• Diffusion-weighted MRI
for prediction and early
treatment assessment of
chemoradiation in head
and neck cancer
• assessment of head and
neck toxicity using CT
Sb
Emerging imaging
technologies – how
functional imaging
will impact our
practice
CL, Ph, RB
• Prostate
• brain
• Lymphoma
• Lung
S
Elderly patients’ treatment:
standards vs. feasibility
• The elderly tsunami
• Importance of age and comorbidity
for the outcome
radiotherapy in head and
neck cancer. a population
based study
• The limits in delivery of chemotherapy
in the elderly:
the breast model
• Comprehensive assessment
in elderly patients with
cancer
14:30 – 15:45
15:45 – 16:15 COFFee bReaK Moving
poster
16:15 – 17:15 S
PP S
PP D
PP PP
session
Elderly patients treatment:
Can imaging be
Why should we do pre-treat-
standards vs. feasibility
quantitative?
ment QA for IMRT when we
• Primary radiotherapy:
CL, RB
didn’t do it for conformal
head and neck
• Multi-centric
therapy?
• neoadjuvant radiotherapy:
calibration of PeT
Lower gI
• Validation of
• adjuvant and definitive
imaging
radiotherapy in elderly
• What can automa-
patients with lung cancer
tic PeT tumour volume
delineation
bring to treatment
planning?
17:30 – 18:00 aWaRD LeCTuRe (IRIDIuM) COMPanY aWaRD LeCTuReS (VaRIan, J. FOWLeR)
eSTRO SCHOOL SYMPOSIuM anD ReCePTIOn
18:00 – 19:00
SESSIONS: TL= Teaching Lecture / S = Symposium /JS = Joint Symposium / D = Debate / PP = Proffered Papers / LI = Look Inside / EU = Session on EU Projects
DISCIPLINES: CL= Clinical / PH= Physics / BRT= Brachytherapy / RB= Radiobiology / RTT= Radiation Technology

BARCELONA • SATuRDAy, 12 MAy 2012
Scientific
cientific PProgramme
rogramme
clInIcal clInIcal InterdIscIplInary physIcs physIcs radIobIology RTT
Normal tissue Radiobiological
principles
Current practice and moving controversies Dosimetry challenges Theragnostic and
imaging in radiotherapy
topIcs
oF the day
TL
Radiobiological
principles: an
overview
TL
Molecular pathology
of normal tissue
effects
TL
Overview of dose volume
parameters used
in clinical practice and
recommendations
(EBRT and brachytherapy)
TL
Small photon field
dosimetry challenges in
relative-absolute and
reference dosimetry
TL
Current practice: new
targeted agents and radiotherapy
in clinical trials
TL
Standards and
uncertainties in
radiotherapy of the
upper abdomen
TL
Current practice and moving
points: lung
08:00 – 08:40
S
Radiobiology
principles:
dose fractionation
• Radiobiological
principles:
what the RTTs
need to know
• Hyperfractionation:
general
overview
• accelerated
treatment in
breast cancer
• Hypofractionation:
general
overview
S
Novel clinical
strategies to reduce
normal tissue injuiry
• Stem cell therapy
to ameliorate
radiation damage
in salivary glands
• attenuation and
reversion of
radiation induced
fibrosis by an anti
CTgF monoclonal
antibody
• Development of
novel mitigators of
radiation damage
S
ultrasound in brachytherapy
• uS physics: basics and
new developments
• uS for treatment
planning in prostate
• uS for treatment
planning in gynaecology
S
Dosimetry challenges
when moving away from
reference conditions
• TRS-398 12 years later:
review of new data and
application to novel
treatment units
• Dosimetric commissioning
of rotational
treatment units
• Dosimetry in strong
magnetic fields: issues
and opportunities
• Dosimetric concepts
based on particle track
structure
S
Novel drugs and RT
CL, RB
• Synthetic lethal approaches
to using drugs
with radiation
• The need and challenge
of introducing biomarkers
in phase 1-2 trials of
radiotherapy and novel
targeted agents
• Design and conduct of
early-phase radiotherapy
trials with targeted
therapeutics
• The head and neck model
S
Complex multimodel
approaches:
upper gI
• Multidisciplinary
management of
operable gastric
cancer
• Complex multimodal
approaches
for oesophagus and
OgJ tumours
• Complex multimodel
approaches
for pancreatic
tumours
S
Critical assessment of the
potential of research strategies
to improve outcome of
advanced NSCLC
• Image-guidance
• Dose escalation and fractionation
• Combined modalities including
chemoradiation and
molecular targeting
• Particle therapy
08:45 – 10:00
10:00 – 10:30 COFFEE BREAK
PP PP PP PP
PP J S
ESTRO – EORTC
CL, Ph, RB, RTT
• Qa and credentialing:
global status and future
challenges
• a radiation oncologist
view on trial Qa
• Qa makes a trial stronger
S
Complex multi-model approaches:
lung
• Chemoradiation In nSCLC:
divided past, common
future?
• Postop radiotherapy/ current
guidelines and moving
points
• Target drugs and radiotherapy
(both nSCLC and SCLC)
10:30 – 11:30
SESSIONS: TL= Teaching Lecture / S = Symposium /JS = Joint Symposium / D = Debate / PP = Proffered Papers / LI = Look Inside / EU = Session on EU Projects
DISCIPLINES: CL= Clinical / PH= Physics / BRT= Brachytherapy / RB= Radiobiology / RTT= Radiation Technology
Page 18 /// FInal announcement /// eSTRO 31 eSTRO 31 /// FInal announcement /// Page 19
clInIcal clInIcal InterdIscIplInary physIcs physIcs radIobIology RTT
HOnORaRY MeMbeRS LeCTuReS
11:45 – 12:30
aWaRD LeCTuRe (bReuR)
12:30 – 13:00
13:00 – 14:30 LunCH anD InDuSTRY SYMPOSIa
S
Radiobiology principles:
dose modifiers
• Is there a need for
interval between drug
and radiotherapy
delivery?
• Side effects with dose
modifier relevant for
RTT: general overview
• Radioprotectors: general
overview
S
heterogeneity in treatment
response: the way to personalised
treatment
• egFR signalling as a basis
for personalised medicine
• The importance of RaS
mutations for targeted
therapy in colon cancer
• Hypoxia signatures predict
benefit from radiosensitisers
PP S
PET and MR imaging possibilities
and pitfalls when used for
radiotherapy
• Impact of image reconstruction
and quantitative analysis
on PeT for radiotherapy
planning
• The use of MRI in radiotherapy
planning: potential
pitfalls and solutions
• Dynamic and diffusion weighted
MRI: how to use it for
radiotherapy
14:30– 15:45 PP PP S
Extreme hypofractionation
CL, Ph, RB, RTT
• biological consideration
of high dose per
fraction
• High dose rate: a new
opportunity?
• Managing delivery of
high dose fraction
• assessment of effect
and outcome
15:45 – 16:15 COFFee bReaK
PP
D
This house believes that
SNPs will be useful predictors
of normal tissue
response in the future
D
This house
believes
that 1%
improved
dosimetric
accuracy
is more
valuable
than 1 mm
less PTV
margin
JS
ESTRO – ASTRO
New technologies
in radiation oncology
are always better:
fact of fiction?
• Protons
• IMRT: the potential
use and benefit of
dose escalation
• IgRT: the challenge
& potential for intraprostatic
boosts
Eu
ARTFORCE
ANDANTE
JS
ESTRO - EANM
The future of radio-isotope
therapies (bone mets, thyroid,
neuroendocrine, lymphoma)
• Radium-223 in the treatment
of advanced prostate cancer
• Translational studies on pretargeted
radio-immunotherapy
of colorectal cancer
• Radiolabelled somatostatin
analogues in neuroendocrine
tumours
16:15 – 17:15
geneRaL aSSeMbLY
17:30 – 19:30
SOCIaL eVenIng
20:00
SESSIONS: TL= Teaching Lecture / S = Symposium /JS = Joint Symposium / D = Debate / PP = Proffered Papers / LI = Look Inside / EU = Session on EU Projects
DISCIPLINES: CL= Clinical / PH= Physics / BRT= Brachytherapy / RB= Radiobiology / RTT= Radiation Technology

BARCELONA • SuNDAy, 13 MAy 2012
Scientific
cientific PProgramme
rogramme
clInIcal clInIcal InterdIscIplInary physIcs physIcs radIobIology RTT
Looking forward Stem cells RTT responsibilities
and involvement in
research
Dose calculation and
optimisation
Predictive biomarkers
in radiotherapy
Current practice and
moving controversies
topIcs
oF the day
TL
RTT responsibilities
and involvement in
research
TL
What is a stem cell and
why should I care
TL
Models for secondary
cancer induction at
radiotherapy dose.
An update
TL
Biological optimisation
in the clinic
TL
New clinical fractionation
models in head
and neck radiation
therapy
TL
Current practice and
moving points: sarcoma
TL
Current practice and
moving points:
primary brain
08:30 – 09:10
S
RTT responsibilities
and involvement in
research
• The role of the imaging
specialist RTT
• From mould to planning
• How to plan and
implement a clinical
research RTT project
in the department
D
how important are
tumour and normal
tissue stem cells in
radiotherapy
S
Nanoparticles in radiotherapy
• green nanotechnology
in molecular
imaging and therapy
• Physical perspective
on radiation
response modulation
of tumours with gold
nanoparticles
• gold nanoparticles as
radiosensitisers
• Monte Carlo simulation
on dose enhancement
S
Advances in dose calculation
and optimisation
algorithms. Improving
planning efficacy and
plan quality
• MCO for IMRT planning
• MCO in radiation
oncology: from priorisation
to interaction
• Fast and accurate
solution of the
boltzmann radiation
transport equation for
radiotherapy. Theoretical
aspects
• Fast and accurate
solution of the
boltzmann radiation
transport equation
for radiotherapy.
Implementation and
validation
S
how deep does hPV
change h&N treatment
strategy?
CL, RB
• epidemiology and
clinical features
• biology and targeting
of HPV
• HPV positive vs. HPV
negative oropharyngeal
carcinoma:
de-escalating vs.
intensified treatment?
S
Prediction of complete
response can enhance
organ preservation in
rectal cancer
• pCR: a subgroup
of patients with
better survival or
a unsafe surrogate
endpoint
• Diffusion MR prediction:
standard
or research
• PeT-CT prediction
of response of rectal
cancer to neoadjuvant
therapy:
standard or research
• Modelling response
prediction on clinical
and imaging
evidences
S
Current practice and
controversies: brain
tumours
• Combination of
targeted drugs with
radiotherapy in
glioblastoma : from
mechanisms to
therapy
• Low grade gliomas
/ treatment
sequence (current
practice and future
trends)
• brain metastases
09:15 – 10:30
10:30 – 11:00 COFFee bReaK
SESSIONS: TL= Teaching Lecture / S = Symposium /JS = Joint Symposium / D = Debate / PP = Proffered Papers / LI = Look Inside / EU = Session on EU Projects
DISCIPLINES: CL= Clinical / PH= Physics / BRT= Brachytherapy / RB= Radiobiology / RTT= Radiation Technology
Page 20 /// FInal announcement /// eSTRO 31 eSTRO 31 /// FInal announcement /// Page 21
clInIcal clInIcal InterdIscIplInary physIcs physIcs radIobIology RTT
S
Comparison studies:
ongoing research
• gynaecological radiotherapy:
a study to
compare 2D gynaecological
radiotherapy
with IMRT: an ongoing
trial in Ireland
• Ongoing research: Fu
data of a moderate
hypo-fractionation
scheme
• Delineation of rectal
carcinoma: comparison
between prone
and supine position
S
MC platforms, getting
MC easy for routine use
in MP
• SMCP - an efficient
Monte Carlo treatment
planning system
• egSnrc, beaMnrc
Eu
MEDRAPET
uLICE
S
Predictive biomarkers
in radiotherapy
CL, Ph, RB
• Preclinical predictive
essays and
platforms
• Do our mother’s
genes influence tolerance
to radiation?
• use in clinical trials
S
head and neck design:
Radiotherapy techniques
requirements
• IMRT for which
patients and for what
benefit?
• IMRT + IgRT and/or
adaptive
• IMRT for nPC
D
This house believes
that there is still a
role for radiotherapy
in intermediate risk
endometrial cancer
11:00 – 12:00
D2
The house believes that biological optimisation supersedes physical optimisation
12:00 – 12:45
SESSIONS: TL= Teaching Lecture / S = Symposium /JS = Joint Symposium / D = Debate / PP = Proffered Papers / LI = Look Inside / EU = Session on EU Projects
DISCIPLINES: CL= Clinical / PH= Physics / BRT= Brachytherapy / RB= Radiobiology / RTT= Radiation Technology

AwArds rds Call all for abstra bstraCts ts
*** ESTRO – VARIAN AWARD ***
prIze deFInItIon
a prize of 7500 € will be given to a radiotherapy professional for research in the field of radiobiology, radiation physics,
clinical radiotherapy or radiation technology.
crIterIa For elIgIbIlIty
Candidates should be:
1. eSTRO members, having completed the submitted work in the previous year.
Submissions should be sent by the candidates or their department heads and may be work done as an individual piece
of research or as a thesis complete in the field of biological, physical and clinical research.
2. Younger than 36. exceptions will be made for female applicants who had to interrupt their research for pregnancy/
maternity reasons; for them the maximum age is fixed at 40.
Candidates should submit:
• a curriculum vitae and a list of publications
• an abstract of the project for eSTRO 31
• an english summary of their work (max 2 pages)
The candidates should commit themselves to write an original paper in english on (part of) the scientific work carried
out. This paper should be based on previously unpublished data and should be written according to the “Instructions to
authors” of the Journal “Radiotherapy and Oncology” in which it will be published, if accepted.
*** ESTRO – JACK FOWLER uNIVERSITy OF WISCONSIN AWARD 2011 ***
a single prize of 1000 € will be given for the best abstract in the field of radiation physics or radiation technology,
submitted for eSTRO 31.
crIterIa For elIgIbIlIty
Candidates should be:
1. eSTRO members.
2. Younger than 36. exceptions will be made for female applicants who had to interrupt their research for pregnancy/
maternity reasons; for them the maximum age is fixed at 40.
Candidates should submit:
• a curriculum vitae,
• a letter from their department head stating that the work has been done by the applicant,
• an abstract on radiation physics or radiation technology for presentation at eSTRO 31.
Applications for awards are to be addressed to:
ESTRO Office • Av. E. Mounierlaan, 83 • 1200 Brussels • Belgium
Tel: +32.2.775 93 40 • Fax: +32.2.779 54 94 • awards@estro.org
DEADLINE FOR SuBMISSION: 16 JANuARy 2012
guIDeLIneS FOR SubMISSIOn OF abSTRaCTS
nOTe: OnLY One abSTRaCT aS PReSenTIng auTHOR Can be SubMITTeD
abSTRaCT SubMISSIOn DeaDLIne: 16 JANuARy 2012 (MIDnIgHT CeT)
gENERAL INSTRuCTIONS
abstracts must be submitted online via the eSTRO website at: www.estro.org.
For questions regarding the online submission process, please e-mail events@estro.org.
REguLATIONS
ESTRO
31
2012
With the submission of an abstract for eSTRO 31, the first (presenting) author:
• accepts responsibility for the accuracy of the abstract and ascertains that all authors are aware of the content before
submission
• accepts to be the contact person for all correspondence related to the abstract and to inform the co-authors about
its status
• accepts to identify any financial interest in products or processes described in the abstract. This includes stock
ownership, membership on any advisory boards, commercially sponsored research or any other substantial relationships.
• Certifies that the information to be reported is for exclusive presentation in the session to which the abstract will be
assigned, if accepted, and that the information will not be presented as such at any commercially sponsored satellite
symposia during the conference
abstracts must be submitted and presented at the conference in english. The Scientific Committee reserves the right to
reject an abstract written in poor english.
abstracts will be anonymised before review to ensure fairness and eliminate possible bias. Therefore it is strictly for-
bidden to include the authors’ names or institutions in the body of the abstracts. Submitted abstracts that include such
references will be penalised by the abstract Reviewing Committee.
During eSTRO 31 a poster session for authors aged 40 or less will be organised. Please make sure your date of birth is
correct in the eSTRO database.
Page 22 /// FInal announcement /// eSTRO 31 eSTRO 31 /// FInal announcement /// Page 23

ABSTRACT SuBMISSION
abstract Format:
Call all for abstra bstraCts ts
• Topic category: choose the topic category that refers to the main subject of the abstract. The Scientific Committee
reserves the right to re-categorise the abstract.
• Presentation preference: authors should indicate the presentation preference (oral, poster or no preference). Please
note that the final decision on the presentation format rests with the Scientific Committee.
• Keywords: authors are required to provide 1 to 3 keywords (different from category).
• Title: abstract titles should be brief and reflect the content of the abstract. The title (maximum 100 characters) is
important since it focuses attention (it is the “showcase” for the presentation). Do not use capital letters in the title
except for words that are always capitalised and do not use non-standard abbreviations.
• body of the abstract: abstracts should be structured in such a way as to include (1) Purpose/Objective; (2) Material/
methods; (3) Results (4) Conclusion.
• The use of standard abbreviations is desirable. a special or unusual abbreviation must be placed (in round brackets)
after the first appearance of the word for which it stands.
• The online abstract submission procedure will not accept abstracts that exceed 2500 characters (body of the abstract,
excluding spaces).
• authors can include one data table in the body of the abstract (this is not included in the number of characters).
• authors can include one black and white image in JPg format. The maximum file size of each image should be 500
Kb. The maximum pixel size of the image is 600(w) x 800(h) pixel. Colour illustrations will appear in black and white.
• equations can be inserted in the text as images (only JPg format).
• The preferred font is Verdana 7.
ABSTRACT SELECTION PROCESS
abstracts submitted for presentation will be reviewed by an international panel of experts in the field of the subject.
abstract review criteria are based on clarity, supporting data, scientific rigour, potential significance, interest in the topic
chosen and innovation or usefulness. Research obviously not yet performed and results not yet obtained will be rejected.
abstracts WIll be selected For one oF the FolloWIng presentatIon Formats:
• Oral presentation: the abstract is selected for oral presentation at any of the proffered paper sessions.
• Poster discussion session: a limited number of the abstracts will be selected for poster presentation. a chairperson
will discuss selected posters with the authors and audience.
• Poster presentation: abstracts that have been selected for presentation in a poster format. The posters are grouped by topic
and are displayed throughout the meeting. Only a limited number of abstracts will be selected for poster presentation.
• e-poster: abstracts are available for viewing in electronic format in special stations available at the conference venue.
Withdrawal of an abstract: abstracts submitted for eSTRO 31 can be withdrawn until 10 February 2012. (To withdraw
your abstract you should send an email to events@estro.org). after this date, withdrawal of abstracts is no longer possible.
abstracts selected for oral / poster discussion / poster presentation should be presented at the meeting. If the
first (presenting) author cannot attend the conference, he / she should assign a replacement and inform the eSTRO
office of the replacement as soon as possible.
notification of outcome of abstract submission will be sent by email by end February 2012.
LATE-BREAKINg ABSTRACTS
ESTRO
31
2012
• The work and/or update must be novel, ground-breaking, of high significance, evidence-based and with scientific merit.
• The work and/or update must be original and not previously have been published or presented at any other scientific meeting.
• The abstract must present timely findings that were not available at the time of the deadline (16 January 2012). The
late breaking abstract deadline is not intended to be a second deadline for abstract submissions.
• a limited number of late-breaking abstracts will be accepted.
• Submissions will be accepted for oral presentation only.
• The deadline for late-breaking abstracts is 20 March 2012.
ABSTRACT TOPIC CATEgORIES
ClInIcal track
1. CnS and haematology
2. Head and neck
3. Lung
4. breast
5. gastrointestinal tumours (upper and lower gI)
6. genitourinary (prostate included)
7. gynaecological tumours
8. Sarcoma
9. Paediatrics
10. elderly
11. Palliation/supportive care/patient support
12. Stereotactic RT
13. Target and volume definition and imaging
14. Health economics
15. Other tumour sites
PhysIcs track
16. basic dosimetry and phantom and detector developments/characterisation
17. Dose measurements
18. Dose calculation
19. Treatment planning and comparisons
20. Treatment plan optimisation
21. Radiobiological modelling
22. Intrafraction motion management
23. Management of interfraction changes
24. Imaging: focus on clinical applications
25. Imaging: focus on Qa and technical aspects
26. Implementation of technology, techniques, clinical
protocols or trials
27. Radiation protection
28. Professional and educational issues
29. Others
radIobIology track
30. Molecular targeted agents and radiotherapy
31. The Dna damage response
32. genomics and proteomics
33. Tumour microenvironment, hypoxia & angiogenesis
34. normal tissue effects: pathogenesis and treatment
35. Predictive assays/prognostic factors
36. novel radiation modalities - particles, high LeT
37. Time dose fractionation
38. Signal transduction
39. Others
RTT track
40. Patient preparation, patient immobilization
and support aids
41. Treatment planning and dose calculation
42. Volume definition, treatment margins and geometric
uncertainties
43. Patient care
44. education and training
Page 24 /// FInal announcement /// eSTRO 31 eSTRO 31 /// FInal announcement /// Page 25

General eneral IInformat
nformatIon on
uPDATED INFORMATION
Please consult the eSTRO website on a regular basis
for updated information: www.estro.org.
CALL FOR ABSTRACTS
abstracts must be submitted online through the eSTRO
website which hosts an electronic abstract submission
form. One abstract as presenting author can be submitted.
Deadline for abstract submission is January 16, 2012.
ONLINE REgISTRATION
Registration to the conference will be exclusively
through our online registration form via the eSTRO
website.
VENuE
CCIb
Rambla Prim 1-17
08019 barcelona, Spain
www.ccib.es
ACCOMMODATION & CITy TOuRS
The official accommodation agent for the conference
will be ultramar.
In close consultation with us they have made a selection
of hotels in barcelona. We advise you to make
your reservation well in advance. Hotel accommodation
is made on a first-come, first-served basis.
If you wish to take a guided tour of the city please
contact:
Teresa Ibañez
ultramar event Management
Diputació 238-244 3a planta
08007 barcelona
Tel.: +34 93 482 71 63 • Fax: +34 93 482 71 54
estro2012@ultramarevents.com
CuRRENCy
The currency in Spain is the euro.
OFFICIAL LANguAgE
The official language of the conference is english. no
simultaneous translation will be provided.
POSTERS
electronic poster stations located in the exhibition
hall and in the poster area will allow you to view the
virtual displays at your leisure and to correspond with
presenters or forward a presentation to a colleague
or home office.
Selected posters will also be displayed in the poster
area during the whole conference.
EXhIBITION
an exhibition featuring equipment and medical publishers
will be held in the exhibition area. The opening of the
exhibition will be on Wednesday May 9, 2012 at 19.30.
The exhibition will remain open from Thursday May 10
to Saturday May 12. entrance is free for all registered
participants and accompanying persons.
Companies and publishers who would like to participate
in the exhibition may obtain more detailed information
from the eSTRO Office.
Contact person:
Valérie Cremades – Industry & exhibition Coordinator
Tel.: +32.2.775.93.41 • Fax.: +32.2.779.54.94
e-mail: vcremades@estro.org
INSuRANCE
The organiser does not accept liability for individual
medical, travel or personal insurance. Participants are
strongly advised to take out their own personal insurance
policies.
In case an unforeseen event would force eSTRO to
cancel the meeting, the Society will reimburse the par-
ticipants the registration fee minus 15% for handling
charges. eSTRO will not be responsible for the refund of
travel and accommodation costs.
LuNChEONS AND REFREShMENTS
The registration fee for the conference includes lunch
and coffee breaks to all participants and exhibitors
wearing their conference badges.
OPENINg CEREMONy & WELCOME RECEPTION
all participants, registered accompanying persons and
company delegates are invited to the official opening
ceremony which will be held in the main auditorium
on Wednesday May 9, 2012 at 18:00. The opening ceremony
will be followed by the welcome reception
which will take place in the exhibition area.
SATELLITE SyMPOSIA
Commercial satellite symposia will be held during lunch
breaks. The programmes of the symposia will be
published in the official Programme book and on the eSTRO
website. For additional information, please contact:
Valérie Cremades – Industry & exhibition Coordinator
Tel.: +32.2.775.93.41 • Fax.: +32.2.779.54.94
e-mail: vcremades@estro.org
SOCIAL ACTIVITIES
• Wednesday, may 9, 2012
all registered participants & accompanying persons
and all company delegates are invited to the
welcome reception which will take place in the
exhibition area as of 19:30 on Wednesday 9 May.
• saturday, may 12 , 2012
all participants and registered accompanying persons
are invited to the special evening which will
take place in an exclusive venue in barcelona.
ESTRO
31
2012
hOW TO REACh BARCELONA
• el prat InternatIonal aIrport is six miles (10 kilometres)
south-west of the centre of barcelona and taxis are
available at the airport 24 hours a day. It takes about
twenty minutes into the centre of town and the fare
is about 18 €. There’s a RenFe train every 30 minutes
to Sants Station (central barcelona) from 6:00 am to
10:30 pm. The fare is about 1.80 € and the journey
takes about 16 minutes in air-conditioned trains with
plenty of luggage space.
• publIc transport In barcelona
The subway is the easiest and fastest way of moving
around the city.
barcelona has got 2 different systems, the subway
with its 5 lines and the FCg, with 2 lines in barcelona
and 4 more lines going to nearby towns.
The bus is certainly a slower transportation but it allows
you to enjoy the city views while moving around.
black and yellow cabs show a green light when free.
Just wave your hand to call them. The meter (it is
compulsory to use them) will indicate the price to
pay, but an extra fee is charged when taking it at
the airport or when you carry luggage with you, etc.
Prices are shown on a sticker inside the cab.
• hoW to reach the congress centre
You can reach the CCIb by metro (Maresme-Forum
station in the yellow line), bus (lines number 7, 36,
41, 43 and 141) and Trambesos (Forum station). all
these stops are located just a few minutes’ walking
distance from the CCIb.
Page 26 /// FInal announcement /// eSTRO 31 eSTRO 31 /// FInal announcement /// Page 27

Regist egistRation ation
ONLINE REgISTRATION
Registering through the eSTRO website is simple and
will only take a few minutes. The eSTRO website can be
consulted at www.estro.org (click “events”, “eSTRO 31”
and then “register online”). Please follow the instructions
included on the electronic registration form before
submitting your registration and do not send it again by
fax or post. Receipt of registration will be acknowledged
electronically.
PAyMENT INFORMATION
Payments can be made either by credit card through
our secured website or by bank transfer.
For payments made by bank transfer 15 € should be
added to the total amount.
For all questions concerning registration and payments,
please contact: events@estro.org.
REgISTRATION FEE
Reduced fees apply when the payment is received before
specific deadlines:
EaRly REgisTRaTion RaTE dEadlinE: 12 JanuaRy, 2012
laTE REgisTRaTion RaTE dEadlinE: aPRil 10, 2012
dEsk REgisTRaTion RaTE: as of aPRil 11, 2012
Please note that in order to register for this event
at the member price you must renew your membership
for 2012.
Registration to eSTRO 31 also gives access to the World
Congress of brachytherapy. See the World Congress of
brachytherapy Final announcement or the eSTRO web-
site for the detailed Scientific Programme.
Registration to eSTRO 31 does not give access to the
Conference pre-meeting courses and the Contouring
workshops.
The registration fee to the conference includes access to
the scientific sessions, including the World Congress of
brachytherapy, the exhibition area, the programme and
abstract books, coffee and lunches, the invitation to the
opening reception and the social evening.
The registration fee for accompanying persons includes
access to the opening ceremony and welcome reception,
the social evening and the exhibition area.
CONFIRMATION OF REgISTRATION
upon receipt of your registration, a confirmation of
your registration will be forwarded to you electronically.
CANCELLATION OF REgISTRATION
In case of cancellation, a refund of the registration fee
minus handling charges of 15% may be obtained up to
3 months before the meeting. between 3 months and 1
month before the meeting, the refund will amount to
50% of the fee. no refund will be possible if the cancellation
is postmarked after april 10, 2012.
Prices DO NOT INCLUDE VAT.
18% VAT will be added at the end of the registration process.
ESTRO
31
2012
conFerence early late desk
deadlInes 12/01/2012 10/04/2012 as oF 11/04/2012
1 day registration RTT member 200 € 200 € 200 €
1 day registration eSTRO member
(exc. RTT)
300 € 300 € 300 €
1 day registration non member 415 € 415 € 415 €
Student * 210 € 245 € 300 €
RTT member 250 € 335 € 440 €
Junior Member 285 € 400 € 545 €
Member 355 € 540 € 685 €
non member 600 € 775 € 955 €
accompanying person ** 130 € 130 € 130 €
pre-meetIng courses
RTT member / Junior member / Student 105 € 155 € 225 €
Member 150 € 190 € 245 €
non member 195 € 235 € 290 €
contourIng Workshops 30 € 55 € 110 €
Prices are without VAT. 18% VAT will be added upon payment.
* To register as a student you should send your updated student card after doing the registration and before paying to jill.barnard@estro.org, Institute
letters are not accepted.
** The registration fee for accompanying persons includes access to the opening cermony and welcome reception, the social evening and the exhibition area.
Page 28 /// FInal announcement /// eSTRO 31 eSTRO 31 /// FInal announcement /// Page 29

Accommod
ccommodAtion tion
uLTRaMaR is the official agent for the eSTRO 31 Conference and will be offering special reduced rates for accommodation.
accommodation has been arranged for the period of the conference (from May 7 th to 13 th May 2012). For earlier arrivals,
later departures or groups with more than 3 persons please contact us: estro2012@ultramarevents.com
To book your accommodation please go to: www.estro-events.org/Pages/eSTRO31.aspx
Hotel accommodation is subject to availability. In case of extension of nights, the effective rate at the moment of the
request will be applied.
From april 9 th on, all reservations will be On ReQueST.
Full payment should be transferred no later than april, 9 th 2012. Please note all reservations will be automatically can-
celled if payment is not received by the mentioned dates.
• until april 9th 2011, no cancellation fees will be applied.
• From april 10th to april 20th , one night will be charged as cancellation penalty.
• no refund will be provided for partial or total cancellations after april 20th onwards, neither for no-shows
• In case of no-shows, the hotel will automatically release the reservation and full payment will be non-refundable.
all changes/cancellations must be received in writing by fax or email. Please do not contact the hotel directly. no other
means of cancellation will be considered.
accommodatIon secretarIat:
Raquel González
ultramar Event Management
Diputació 238-244 3a planta
08007 Barcelona
Tel.: +34 93 482 72 46 • Fax: +34 93 482 71 54
estro2012@ultramarevents.com
www.estro2012accommodation.com
ESTRO
31
2012
hOTELS CATEgORy SINgLE DOuBLE
Me barcelona 5* 243 € 265 €
Yacht Hotel 5* 240 € 240 €
Medinaceli 4* 200 € 250 €
aC barcelona 4* 211 € 233 €
Hilton Diagonal Mar 4* 210 € 240 €
barcelona Princess 4* 200 € 222 €
Diagonal Zero 4* 190 € 210 €
Hesperia del Mar 4* 179 € 189 €
Vincci Marítimo 4* 155 € 175 €
Tryp Condal Mar 4* 168 € 179 €
Confortel barcelona 4* 162 € 173 €
novotel barcelona City 4* 160 € 180 €
Silken Diagonal barcelona 4* 160 € 175 €
gbb Front Marítim 4* 160 € 172 €
Rafael Diagonal Port 4* 157 € 172 €
attica 21 barcelona Mar 4* 157 € 169 €
barceló atenea Mar 4* 115 € 125 €
Holiday Inn barcelona City 4* 104 € 104 €
Hotel del Mar 3* 145 € 175 €
Hotel glories 3* 92 € 129 €
Hotel Ibis barcelona Pza glories 2* 107 € 115 €
Hotel Santa Marta 2* 90 € 105 €
Rates are per room, per night, including taxes and breakfast
Page 30 /// FInal announcement /// eSTRO 31 eSTRO 31 /// FInal announcement /// Page 31

PuRPOSE
MeMbership bership
eSTRO, The european SocieTy for Radiotherapy and
Oncology, was founded in Milan in September 1980.
The purpose of eSTRO is to foster, in all its aspects, radiotherapy
(also known as radiation oncology). To fulfill its
purpose eSTRO will:
a. Develop and promote standards of education in radiotherapy
and clinical oncology,
b. Promote standards of practice in radiotherapy, clinical
oncology and related subjects,
c. Stimulate the exchange of scientific knowledge in all
related fields,
d. Strengthen the clinical speciality of radiotherapy and
clinical oncology in relation to other specialities and
professions involved in cancer management,
e. encourage co-operation with international, regional
and national societies and bodies representing radiotherapy,
clinical oncology and related subjects,
f. Facilitate research and development in radiotherapy,
clinical oncology and related subjects.
package
Society
Dissemination
Professional
Voting right, eligible for councils, committees,
working groups, faculties, etc…
access to green and Red Journal,
reports, webcast library, discount on
eSTRO publications, etc…
Reduced fee for eSTRO events and courses,
eligible for grants and awards, etc…
BENEFITS OF ESTRO MEMBERShIP
Improve your proFessIonal development by partIcIpatIng In the
socIety’s ‘InstItutIonal’ actIvItIes
• Opportunity to become a member of a Council, Committee
or a Specialist in a Working group,
• eligible for grants and awards,
• eligible for eSTRO Fellow,
• Possibility of networking with other professionals/
experts in your field,
• Invitation to contribute to conferences (as a scientific
Committee member or as a speaker).
keep updated WIth ongoIng research
• Personal subscription to the green Journal + on line
access,
• On line access to the Red Journal,
• Regular mailings of eSTRO newsletters and reports.
get dIscounts
• Discount on eSTRO Publications,
• Discount on conference registration fees,
• Discount on eSTRO School programmes,
• Reduced subscription to the European Journal of
Cancer.
membershIp type
Full assocIate
Full access no access
Full access Conditional access
Full access Conditional access
FOR FuRThER INFORMATION PLEASE CONTACT:
eSTRO Office • av. e. Mounier 83 • 1200 brussels • belgium
Tel: + 32 2 775 93 40 • Fax: + 32 2 779 54 94 • email: membership@estro.org
NOTE: RENEWAL OF ESTRO MEMBERShIP FOR 2012 WILL BE POSSIBLE AS OF OCTOBER, 2011.
ESTRO
31
2012
Page 32 /// FInal announcement /// eSTRO 31 eSTRO 31 /// FInal announcement /// Page 33